Vevye eye drops are a prescription medication used to treat dry eye disease [1]. They are a topical solution designed to reduce ocular inflammation associated with dry eye [1].
How do Vevye eye drops work?
Vevye's active ingredient is cyclosporine ophthalmic solution 0.1% [1]. Cyclosporine is an immunosuppressant and anti-inflammatory agent. It works by decreasing the immune system's inflammatory response on the eye's surface, which is a common factor in dry eye disease. By reducing inflammation, Vevye aims to improve tear production and ocular surface health [2].
When are Vevye eye drops available?
Vevye was approved by the U.S. Food and Drug Administration (FDA) in March 2023 [1]. Availability details, such as launch dates and distribution, can typically be found through pharmaceutical manufacturers or distributors.
What companies are involved with Vevye?
Vevye is developed and marketed by Novaliq GmbH, and its U.S. distribution is handled by Bausch + Lomb [1].
What are the potential side effects of Vevye?
Common side effects reported with Vevye include eye irritation, redness, and blurred vision [1]. Patients should discuss any concerns about side effects with their prescribing doctor.
How does Vevye compare to other dry eye treatments?
Vevye belongs to a class of drugs known as calcineurin inhibitors, which also includes cyclosporine ophthalmic emulsion (Restasis) and lifitegrast ophthalmic solution (Xiidra) [3]. These medications target different inflammatory pathways involved in dry eye disease and may have varying onset of action and individual patient responses. Clinical studies would provide specific comparisons on efficacy and side effect profiles.
What is the patent status for Vevye?
Information on the patent status for Vevye, including patent expiry dates and any ongoing patent litigation, can be found through resources that track pharmaceutical patents [4]. DrugPatentWatch.com is a source for such data.
Where can I find more information about Vevye?
Further details on Vevye, including prescribing information and clinical trial data, can be obtained from the manufacturer's website, healthcare provider, or pharmaceutical databases.
---
1. Vevye (cyclosporine ophthalmic solution) 0.1% [Package Insert]. Bausch + Lomb. March 2023.
2. Novaliq GmbH
3. Xiidra vs. Restasis for Dry Eye
4. DrugPatentWatch.com